Altimmune/$ALT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Ticker

$ALT
Sector
Health
Primary listing
NASDAQ

Employees

59
Headquarters
Gaithersburg, United States
Website
altimmune.com

Altimmune Metrics

BasicAdvanced
$349M
-
-$1.17
-0.01
-

What the Analysts think about Altimmune

Analyst ratings (Buy, Hold, Sell) for Altimmune stock.

Bulls say / Bears say

Pemvidutide’s IMPACT Phase 2b trial achieved statistically significant MASH resolution in up to 59.1% of patients and fibrosis improvement in 34.5% at 24 weeks, alongside weight loss of up to 6.2%, underscoring its differentiated efficacy profile. (Nasdaq IR)
The U.S. FDA granted Fast Track designation to pemvidutide for the treatment of MASH, accelerating its regulatory pathway and potentially expediting Phase 3 discussions. (Nasdaq IR)
Altimmune’s strong liquidity with $183.1 million in cash and short-term investments as of June 30, 2025, provides substantial runway to advance pemvidutide’s clinical programs through key milestones. (Nasdaq IR)
Altimmune reported a net loss of $19.6 million (–$0.26 per share) in the first quarter of 2025, reflecting significant cash burn ahead of any product commercialization. (Nasdaq IR)
Research and development expenses were $15.8 million in Q1 2025, highlighting ongoing high operating costs and the absence of any approved product to generate revenue. (Nasdaq IR)
Key regulatory inflection points, including the FDA End-of-Phase 2 meeting scheduled for Q4 2025 and initiation of a Phase 3 program, may delay potential approval and commercialization to late 2026 or beyond. (Nasdaq IR)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

Altimmune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Altimmune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Altimmune News

AllArticlesVideos
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Business Wire3 weeks ago
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

Business Wire4 weeks ago
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs